×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
COGT – cogent biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
COGT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
01:34 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
11/13
08:06 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.
11/13
12:45 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
11/12
08:00 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Medium
Report
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
11/5
09:00 am
cogt
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
High
Report
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
11/4
08:19 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
10/24
08:08 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
10/23
07:00 am
cogt
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Low
Report
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
08:00 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Point72 Asset Management, L.P.
High
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Point72 Asset Management, L.P.
11/14
05:47 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners II, L.P.
High
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners II, L.P.
11/14
04:06 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: COMMODORE CAPITAL LP
Medium
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: COMMODORE CAPITAL LP
11/14
03:53 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Low
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
11/14
12:25 pm
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Kynam Capital Management, LP
Low
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Kynam Capital Management, LP
11/12
09:46 am
cogt
Form 10-Q Cogent Biosciences, Inc. For: Sep 30
Low
Report
Form 10-Q Cogent Biosciences, Inc. For: Sep 30
11/12
09:36 am
cogt
Form 8-K Cogent Biosciences, Inc. For: Nov 12
Low
Report
Form 8-K Cogent Biosciences, Inc. For: Nov 12
11/7
09:25 am
cogt
Form SC 13G/A Cogent Biosciences, Inc. Filed by: FMR LLC
Low
Report
Form SC 13G/A Cogent Biosciences, Inc. Filed by: FMR LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: